BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1)

March 3, 2016 8:00 AM UTC

Mouse studies suggest inhibiting EGLN2 could help prevent cardiac injury in patients at risk of MI. In a mouse model of ischemia/reperfusion injury-induced MI, pretreatment or treatment with an EGLN2 ...